Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
StemCell2MAX logo — company profile

StemCell2MAX

Founded 2015 2-10 employees Grant Biotechnology, Health Care

General Information

Company Name StemCell2MAX
Founded Year 2015
Employees 2-10
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with StemCell2MAX. To contact StemCell2MAX, visit stemcell2max.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does StemCell2MAX compare?

A PDF of StemCell2MAX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting StemCell2MAX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About StemCell2MAX

StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use.

No funding data available for StemCell2MAX yet.

StemCell2MAX Alternatives & Competitors

View All Alternatives
StemCell2MAX vs
Cord Blood Center HQ
Cord Blood Center HQ Switzerland

more cells, more life

24 employees
Biotechnology, Health Care
StemCell2MAX vs
KBP Biosciences
KBP Biosciences United States

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

Series A
40 employees
Biotechnology, Health Care
StemCell2MAX vs
MICA Biosystems
MICA Biosystems United Kingdom

An innovative and dynamic biotech start-up, unlocking the potential of stem cells and nanotechnology...

Grant
9 employees
Biotechnology, Health Care
View all alternatives

FAQ About StemCell2MAX

StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX...
StemCell2MAX was founded in 2015.
StemCell2MAX operates in Biotechnology and Health Care.
StemCell2MAX has approximately 2-10 employees.
Top alternatives and competitors to StemCell2MAX include Cord Blood Center HQ, KBP Biosciences, MICA Biosystems, iRepertoire, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
StemCell2MAX and Cord Blood Center HQ are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for StemCell2MAX, https://bouncewatch.com/company/stemcell2max, updated 15 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes